Publication 2024
621.
Latosinska A, Frantzi M, Siwy J.
Peptides as "better biomarkers"? Value, challenges, and potential solutions to facilitate implementation
Mass Spectrom Rev. 2024, 43(6):1195-1236. Epub 2023 Jun 26.
620.
An DW, Yu YL, Martens DS, Latosinska A, Zhang ZY, Mischak H, Nawrot TS, Staessen JA.
Statistical approaches applicable in managing OMICS data: Urinary proteomics as exemplary case
Mass Spectrom Rev. 2024, 43(6):1237-1254. Epub 2023 May 4.
619.
Jaimes Campos MA, Kabić S, Latosinska A, Anicic E, Siwy J, Dragušica V, Rupprecht H, Catanese L, Keller F, Perco P, Gomez- Gomez E, Beige J, Vlahou A, Mischak H, Vukelić D, Križan T, Frantzi M
medRxiv 2024.10.30.24316342
618.
Siwy J, Keller F, Banasik M, Peters B, Dudoignon E, Mebazaa A, Gülmez D, Spasovski G, Salgueira Lazo M, Rajzer MW, Fuławka L, Dzitkowska-Zabielska M, Mischak H, Hecking M, Beige J, Wendt R, and UriCoV Working Group.
Mortality Risk and Urinary Proteome Changes in Acute COVID-19 Survivors in the Multinational CRIT-COV-U Study
Biomedicines 2024, 12(9):2090.
617.
An D, Martens D, Mokwatsi G, Yu YL, Chori B, Latosinska A, Mayer G, Kruger R, Mels C, Delles C, Stolarz-Skrzypek K, Nawrot T, Li Y, Mischak H, Staessen J.
O67 Urinary proteomic profiling reveals molecular cues underlying higher hypertension susceptibility in Blacks than Whites
Journal of Hypertension 2024, 42(Suppl3): e32.
616.
Yu YL, Martens DS, An DW, Chori B, Latosinska A, Siwy J, Odili AN, Stolarz-Skrzypek K, Maestre GE, Asayama K, Li Y, Verhamme P, Allegaert K, Mischak H, Nawrot TS, Staessen JA.
Osteoporosis in Relation to a Bone-Related Aging Biomarker Derived from the Urinary Proteomic Profile: A Population Study
Aging Dis. 2024, 16(1):633-644. Online ahead of print.
615.
Frattini T, Devos H, Makridakis M, Roubelakis MG, Latosinka A, Mischak H, Schanstra JP, Vlahou A, Saulnier-Blache JS.
Benefits and limits of decellularization on mass-spectrometry-based extracellular matrix proteome analysis of mouse kidney
Proteomics. 2024, 24(17):e2400052. Epub 2024 Jun 19.
614.
Latosinska A, Siwy J, Mischak H.
Multiomics: paving the path towards personalized prevention of hypertension
J Hypertens. 2024, 42(6):962-964. Epub 2024 May 1.
613.
Yu YL, Siwy J, An DW, González A, Hansen T, Latosinska A, Pellicori P, Ravassa S, Mariottoni B, Verdonschot JA, Ahmed F, Petutschnigg J, Rossignol P, Heymans S, Cuthbert JJ, Girerd N, Clark AL, Verhamme P, Nawrot TS, Janssens S, Cleland JG, Zannad F, Diez J, Mischak H, Ferreira JP, Staessen JA; HOMAGE investigators.
Urinary proteomic signature of mineralocorticoid receptor antagonism by spironolactone: evidence from the HOMAGE trial
Heart. 2024, 110(19):1180-1187. Epub 2024 May 9.
612.
Lauder L, Siwy J, Mavrogeorgis E, Keller F, Kunz M, Wachter A, Emrich IE, Böhm M, Mischak H, Mahfoud F.
Impact of Renal Denervation on Urinary Peptide-Based Biomarkers in Hypertension
Hypertension. 2024, 81(6):1374-1382. Epub 2024 Apr 4.
611.
Mavrogeorgis E, Kondyli M, Mischak H, Vlahou A, Siwy J, Rossing P, Campbell A, Mels CMC, Delles C, Staessen JA, Latosinska A, Persu A.
Multiple urinary peptides are associated with hypertension: a link to molecular pathophysiology
J Hypertens. 2024, 42(8):1331-1339. Epub 2024 Mar 28.
610.
Faguer S, Piedrafita A, Sanz AB, Siwy J, Mina IK, Alves M, Bousquet P, Marcheix B, Casemayou A, Klein J, Minville V, Breuil B, Ortiz A, Schanstra JP.
Performances of acute kidney injury biomarkers vary according to sex
Clin Kidney J. 2024, 17(5):sfae091. eCollection 2024 May.
609.
Heidegger I, Frantzi M, Salcher S, Tymoszuk P, Gomez-Gomez E, Lendinez Cano G, Mischak H, Vlahou A, Pircher A.
A0562 - First description of a collagen score outperforming PSA, age and mpMRI in diagnosis of significant prostate cancer
European Urology 2024, 85(Suppl1): S1464
608.
Roa FJ, Roubelakis MG, Paschidis K, Van Creij NCH, Makridakis M, Tserga A, Vlahou A, Santer FR, Holm PS, Hoffmann MJ, Puhr M, Mokou M, Frantzi M, Latosinska A, Mischak H, Culig Z, Pichler R.
A0868 - Amiodarone, an anti-arrhythmic drug, is a new repurposed drug for bladder cancer therapy
European Urology 2024, 85(Suppl1): S1905
607.
Rambabova Bushljetikj I, Trajceska L, Bushljetikj O, Mischak H, Spasovski G.
WCN24-1390 Association of urinary proteomics with the kidney allograft failure risk and left ventricular dysfunction at 48 months after transplantation
Kidney International Reports 2024, 9(4,Suppl): S465
606.
Jaimes Campos MA, Kabić S, Latosinska A, Anicic E, Siwy J, Dragušica V, Rupprecht H, Catanese L, Keller F, Perco P, Gomez-Gomez E, Beige J, Vlahou A, Mischak H, Vukelić D, Križan T, Frantzi M.
A synthetic data generation pipeline to reproducibly mirror high-resolution multi-variable peptidomics and real-patient clinical data
medRxiv. 2024. doi: https://doi.org/10.1101/2024.10.30.24316342
605.
Siwy J, Wendt R, Peters B, Dudoignon E, Banasik M, Hecking M, Spasovski G, Mischak H, Beige J.
#1466 Age- and kidney function-dependent life expectancy of patients after COVID-19
Nephrol Dial Transplant. 2024, 39(Suppl1):i917-18.
604.
Lumi R, Petri S, Siwy J, Latosinska A, Raad J, Zürbig P, Skripuletz T, Mischak H, Beige J.
Small peptide CSF fingerprint of amyotrophic lateral sclerosis
PLoS One. 2024, 19(4):e0302280.
603.
Jaimes Campos MA, Mavrogeorgis E, Latosinska A, Eder S, Buchwinkler L, Mischak H, Siwy J, Rossing P, Mayer G, Jankowski J.
Urinary peptide analysis to predict the response to blood pressure medication
Nephrol Dial Transplant. 2024, 39(5):873-883. Epub 2023 Oct 31.
602.
Mavrogeorgis E, Valkenburg S, Siwy J, Latosinska A, Glorieux G, Mischak H, Jankowski J.
Integration of Urinary Peptidome and Fecal Microbiome to Explore Patient Clustering in Chronic Kidney Disease
Proteomes 2024, 12(2):11.
601.
Rupprecht H, Catanese L, Amann K, Hengel FE, Huber TB, Latosinska A, Lindenmeyer MT, Mischak H, Siwy J, Wendt R, Beige J.
Assessment and Risk Prediction of Chronic Kidney Disease and Kidney Fibrosis Using Non-Invasive Biomarkers
Int J Mol Sci. 2024, 25(7):3678.
600.
Catanese L, Rupprecht H, Huber TB, Lindenmeyer MT, Hengel FE, Amann K, Wendt R, Siwy J, Mischak H, Beige J.
Non-Invasive Biomarkers for Diagnosis, Risk Prediction, and Therapy Guidance of Glomerular Kidney Diseases: A Comprehensive Review
Int J Mol Sci. 2024, 25(6):3519.
599.
Mina IK, Mavrogeorgis E, Siwy J, Stojanov R, Mischak H, Latosinska A, Jankowski V.
Multiple urinary peptides display distinct sex-specific distribution
Proteomics. 2024, 24(5):e2300227. Epub 2023 Sep 26.
598.
Mavrogeorgis E, He T, Mischak H, Latosinska A, Vlahou A, Schanstra JP, Catanese L, Amann K, Huber TB, Beige J, Rupprecht H, Siwy J.
Urinary peptidomic liquid biopsy for non-invasive differential diagnosis of chronic kidney disease
Nephrol Dial Transplant. 2024, 39(3):453-462. Epub 2023 Sep 11.
597.
Yu YL, Huang QF, An DW, Raad J, Martens DS, Latosinska A, Stolarz-Skrzypek K, Van Cleemput J, Feng YQ, Mischak H, Allegaert K, Verhamme P, Janssens S, Nawrot TS, Staessen JA.
OSTEO18, a novel urinary proteomic signature, associated with osteoporosis in heart transplant recipients
Heliyon. 2024, 10(2):e24867.
596.
Brasseler M, Mischak H, Schanstra JP, Michel JM, Pape L, Felderhoff-Müser U.
Gestational Age-Related Urinary Peptidome Changes in Preterm and Term Born Infants
Neonatology. 2024, 121(3):305-313. Epub 2024 Feb 21.